CCL16

Across TCGA pan-cancer cohorts, CCL16 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCL16 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CCL16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCL16 expression acts as an unfavorable survival marker.

SKCM, LGG, and HNSC are the cancer types where CCL16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.208	0.622	.005	20	view →
LGG	DFS	Median	All	0.185	0.738	.003	12	view →
HNSC	OS	Median	All	0.139	0.685	.003	12	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCL16–SKCM (DFS)

Open the SKCM breakdown →